FDA panel endorses first-of-a-kind cancer blood test from Grail
An FDA advisory committee voted to back GRAIL's Galleri multi-cancer early detection blood test, pushing the diagnostic tool closer to formal regulatory approval. FDA staff stated that the data package met predefined trial endpoints for accuracy and clinical performance. Recent trial results for Galleri showed higher detection rates for multiple cancers and fewer late-stage diagnoses. GRAIL anticipates an agency decision on the test in early 2027. Meanwhile, the company reported third-quarter 2026 test revenue growing 14 percent year-over-year to $37.3 million alongside a net loss of $103.6 million.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ An FDA advisory committee backed GRAIL's Galleri multi-cancer early detection screening test during a review.
- ✓ FDA staff stated that Galleri's data package met predefined trial endpoints for accuracy and clinical performance.
- ✓ GRAIL expects an FDA decision on the Galleri multi-cancer blood test in early 2027.
- ✓ In the third quarter of 2026, Galleri test revenue grew 14 percent year-over-year to $37.3 million with test volume increasing 24 percent to over 56,000.
What changed
Recent financial reporting and trial outcome details from the third quarter of 2026 joined the panel backing to clarify the test's market and regulatory trajectory.
Live updates
-
FDA Advisory Panel Backs GRAIL Multi-Cancer Screening Blood Test
An FDA advisory committee voted to back GRAIL's Galleri multi-cancer early detection blood test, pushing the diagnostic tool closer to formal regulatory approval. FDA staff stated that the data package met predefined trial endpoints for accuracy and clinical performance. Recent trial results for Galleri showed higher detection rates for multiple cancers and fewer late-stage diagnoses. GRAIL anticipates an agency decision on the test in early 2027. Meanwhile, the company reported third-quarter 2026 test revenue growing 14 percent year-over-year to $37.3 million alongside a net loss of $103.6 million.
Why it matters
The Galleri screening test evaluates blood draws to help identify more than 50 types of cancer in early, more treatable stages. While the advisory committee endorsed the tool by a 7 to 2 vote following a September review, critics note that definitive evidence showing the test actually reduces overall cancer deaths remains lacking.
What is confirmed
- An FDA advisory committee backed GRAIL's Galleri multi-cancer early detection screening test during a review.
- FDA staff stated that Galleri's data package met predefined trial endpoints for accuracy and clinical performance.
- GRAIL expects an FDA decision on the Galleri multi-cancer blood test in early 2027.
- In the third quarter of 2026, Galleri test revenue grew 14 percent year-over-year to $37.3 million with test volume increasing 24 percent to over 56,000.
- GRAIL reported a net loss of $103.6 million for the third quarter of 2026.
Still unconfirmed
- Definitive evidence that the Galleri test reduces cancer deaths remains lacking.
What to watch next
- An official FDA regulatory decision on the Galleri multi-cancer blood test expected in early 2027.
- Future developments regarding broader access and insurance reimbursement upon FDA approval.
confidence 95%Sources used for this update (6)
- finuty.com — GRAIL (GRAL) Jumps as FDA Advisory Panel Backs Its…
- simplywall.st — GRAIL (GRAL) Wins FDA Panel Backing As Galleri Trial Results ...
- www.phillytrib.com — Blood test could screen for 50 cancers. Here’s why it’s ...
- www.medicaldaily.com — GRAIL Expects FDA Decision on Galleri Multi-Cancer Blood Test ...
- chetnagle.substack.com — The $949 Blood Test That Finds Cancer - chetnagle.substack.com
- pluang.com — FDA panel backs GRAIL's Galleri cancer detectio... | Pluang
-
FDA Advisory Panel Backs GRAIL Multi-Cancer Screening Test
An advisory committee for the Food and Drug Administration backed GRAIL's Galleri multi-cancer early detection screening test, voting 7 to 2 in favor of the diagnostic tool during a September 23 review. Dr. Victor van Berkel, a thoracic surgeon with UofL Health, and nine other doctors served on the panel to evaluate the blood draw for safety and effectiveness. The revolutionary screening test can help identify more than 50 types of cancer in their earliest and more treatable stages. Following the recommendation, GRAIL's stock price surged and closed above two weeks of highs on volume that nearly doubled.
Why it matters
The Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory reviewed the Galleri test to determine its viability for early detection across numerous cancer types. Regulatory review will determine the final federal determination for the diagnostic tool. Wall Street and companies working on multi-cancer early detection responded favorably to the recommendation.
What is confirmed
- An advisory committee for the Food and Drug Administration backed GRAIL's Galleri multi-cancer early detection screening test with a 7 to 2 vote on September 23.
- Dr. Victor van Berkel, a thoracic surgeon with UofL Health, served on the ten-doctor panel that vetted the blood test for safety and effectiveness.
- The Galleri test can help identify more than 50 types of cancer in the earliest and more treatable stages.
- GRAIL stock closed above two weeks of highs on volume that nearly doubled following the September panel decision.
What to watch next
- Final federal regulatory determination from the Food and Drug Administration for the Galleri diagnostic test.
- Further stock performance and market movement for GRAIL.
confidence 100%Sources used for this update (7)
- badgerherald.com — A new era in cancer detection: Exact Science’s Cancerguard is ...
- traderspro.substack.com — GRAIL, Inc. (GRAL): First Test of Its Kind Reviewed
- www.thegoodlifesv.com — FDA Committee Approves Multi-Cancer Early Detection
- article.wn.com — Louisville doctor vetted new blood test that screens for 50 ...
- finance.yahoo.com — GRAIL, Inc. (GRAL) Surged After FDA Panel Backed Its Cancer ...
- www.targetedonc.com — FDA Oncology Roundup: October 2026 Approvals and Submissions
- www.marketbeat.com — Guardant Health (GH) FDA Approvals, PDUFA Dates & Drug Alerts ...
-
FDA Panel Backs Grail Galleri Multi-Cancer Blood Test
An advisory committee for the Food and Drug Administration backed Grail's Galleri multi-cancer early detection screening test, despite the largest multi-cancer screening trial in history missing its primary goal. The panel voted 7 to 2 in favor of the diagnostic tool during a review on September 23. Wall Street and companies working on multi-cancer early detection responded favorably to the recommendation, pushing Grail's stock price higher. However, the decision remains controversial due to concerns regarding the test's performance in major clinical evaluations. Regulatory review will determine the final federal determination for the pioneering diagnostic test.
Why it matters
The review of the Galleri screening test marks a critical milestone for multi-cancer early detection diagnostics. Grail's test is designed to identify DNA fingerprints associated with more than 50 different types of cancer. While investors and industry developers view the panel recommendation as a positive sign for the sector, the path forward involves sorting out complicated clinical data and nuanced panel opinions.
What is confirmed
- An FDA advisory committee panel recommended regulatory approval of Grail's multi-cancer early detection screening test on September 23.
- The FDA panel voted 7 to 2 to approve the test.
- The Galleri screening test is designed to detect multiple cancers.
- Wall Street and companies working on multi-cancer early detection responded favorably to the panel opinion, and Grail's stock jumped.
What to watch next
- Final federal regulatory determination by the Food and Drug Administration regarding the Galleri test commercialization.
- Further analysis of the major clinical trial data and primary endpoints by health systems.
confidence 100%Sources used for this update (8)
- www.centraloregondaily.com — A controversial, cancer-detecting blood test just got backed ...
- www.fda.gov — About FDA | FDA - U.S. Food and Drug Administration
- www.mystrategist.com — MedTech Strategist - The Controversy Over Multi-Cancer Early ...
- fr.wikipedia.org — Food and Drug Administration — Wikipédia
- www.futura-sciences.com — Définition | FDA : qu'est-ce que c'est ? | santé - Futura
- news.oatmealhealth.com — 142,250 People, One Missed Endpoint: What the FDA Galleri ...
- piqmarkets.com — Blood test for 50 cancers wins FDA approval, promising ...
- earlysignaldiagnostics.com — EarlySignal Diagnostics Attends World Clinical ...
-
FDA Advisory Panel Endorses Grail Galleri Multi-Cancer Test
An FDA advisory council endorsed Grail's Galleri multi-cancer early detection blood test, moving the diagnostic tool closer to potential federal approval. This decision occurs despite criticisms that the test performed poorly in its own major clinical trial, including the NHS-Galleri trial. Critics raise concerns that the screening tool could increase false-positive results and lead to billions of dollars in wasted expenditures. Cancer experts remain divided regarding the promise and limitations of the test as regulatory review proceeds toward a final federal determination.
Why it matters
The Galleri screening test utilizes two 10 milliliter tubes of venous blood to identify cancer signals. While the advisory panel endorsement pushed Grail stock to a 12-month high, the diagnostic still faces considerable uncertainty regarding long-term cost-benefit evaluations and whether insurance companies will cover the pricing model.
What is confirmed
- An FDA advisory council recommended approving Grail's Galleri multi-cancer blood test.
- The NHS-Galleri trial served as a test for the multicancer blood detection technology.
Still unconfirmed
- Grail's Galleri multicancer blood test failed its own large trial.
- The FDA advisory council endorsed by RFK Jr. would increase false positives and waste billions of dollars.
What to watch next
- Final federal approval decision by the Food and Drug Administration
- Decisions by insurers regarding coverage and pricing models for the Galleri test
confidence 80%Sources used for this update (3)
- geneticliteracyproject.org — Viewpoint: RFK Jr.’s stacked FDA advisory council endorses ...
- www.medtechdive.com — 5 doctors weigh in on the promise, limitations of Grail’s ...
- www.sensible-med.com — A Formal Review of the Grail Cancer Detection Trial
-
Grail Blood Test Faces Insurance Hurdles After FDA Win
Grail stock reached a 12-month high following an advisory panel endorsement from the US Food and Drug Administration for its Galleri multi-cancer early detection test. Despite moving closer to potential federal approval, the diagnostic tool confronts significant hurdles regarding insurance coverage and long-term cost-benefit evaluations. Insurers remain cautious about pricing models and whether they will pay for the test, even as orders grow and researchers highlight its ability to identify cancer signals from two 10 milliliter tubes of venous blood.
Why it matters
The recent advisory panel win acts as a positive de-risking event for Grail, though commercial viability depends heavily on broader insurer adoption and final regulatory clearance. Unlike traditional single-cancer screenings or failed historical multi-test promises, Galleri uses venous blood samples to screen for roughly 50 different types of cancer. However, analysts note that critical late-stage endpoints require additional evidence, leaving insurance reimbursement rates as the primary barrier to market success.
What is confirmed
- An advisory panel to the US Food and Drug Administration concluded that Grail's early cancer detection test is a milestone win.
- Grail stock hit a 12-month high after its FDA panel win.
- Insurers remain cautious about the long-term cost-benefit profile of multi-cancer early detection.
Still unconfirmed
- Insurers may refuse to cover the Galleri test entirely due to missing late-stage cancer endpoint data.
What to watch next
- Final US Food and Drug Administration approval decision for Grail's Galleri test
- Announcements regarding insurance coverage and reimbursement pricing models
- Release of additional clinical trial data addressing late-stage cancer endpoints
confidence 90%Sources used for this update (17)
- www.fda.gov — Food | FDA
- www.wral.com — AP Health News and Reporting Coverage, page 3 | WRAL
- docs.x.com — X API changelog and release notes - X
- www.fda.gov — Drug Approvals and Databases | FDA
- hgbr.org — Grail Faces Pricing Hurdles Following FDA Advisory Panel ...
- www.fool.com — Grail Stock Hit a 12-Month High After Its FDA Panel Win. But ...
- www.manilatimes.net — Science & Technology | The Manila Times
- www.dailybreeze.com — Men invited to Cancer Support Community South Bay’s ‘Girls Night Out’ fundraiser for first time
- www.yahoo.com — Elizabeth Holmes Promised to Revolutionize Blood Testing. Instead, Theranos Became a Massive Fraud.
- www.medicaldaily.com — Natera's Multi-Cancer Blood Test Gets FDA Breakthrough Status ...
- www.pharmawire.org — Grail's cancer blood test nears landmark FDA approval, but ...
- drugnews.com.tw — Has Cancer Detection from a Blood Sample Really Arrived?
-
FDA Advisory Panel Backs Grail Multi-Cancer Blood Test
An FDA advisory panel has endorsed a multi-cancer blood test developed by Grail, moving the diagnostic tool closer to potential federal approval. The testing mechanism, known as Galleri, aims to identify signs of roughly 50 different cancers from a single blood draw in apparently healthy individuals. Federal health advisers supported the diagnostic while issuing warnings about its use. Grail shares experienced an increase following the advisory panel decision as the technology edges closer to the commercial market.
Why it matters
The U.S. Food and Drug Administration regulates human medical devices and biological products to protect public health and ensure safety and efficacy. Early detection tools capable of screening for numerous malignancies from a simple blood draw represent a significant shift in oncological diagnostics. Regulatory endorsement from an expert panel brings the developer closer to formal agency authorization.
What is confirmed
- An FDA advisory panel endorsed a multi-cancer blood test from Grail.
- Grail's testing mechanism is called Galleri.
- The test can screen for about 50 different cancers from a single blood draw.
- Federal health advisers endorsed the blood test to spot signs of various cancers in apparently healthy people.
Still unconfirmed
- Federal health advisers warned about the blood test while giving their endorsement.
What to watch next
- Final regulatory decision by the U.S. Food and Drug Administration regarding the Grail cancer blood test.
- Commercial market launch steps following any potential FDA approval.
confidence 95%Sources used for this update (4)
- www.cherokeephoenix.org — FDA panel endorses first-of-a-kind cancer blood test from ...
- www.wral.com — AP Science News and Reporting Coverage, page 19 | WRAL
- www.nasmeddiagnostic.com — Multi-Cancer Blood Test Moves Closer to FDA Approval
- www.thedailyupside.com — Grail Jumps as Cancer Test Nears Market - The Daily Upside
-
FDA Regulatory Scope and Authority for Health and Safety
The U.S. Food and Drug Administration operates as a federal agency within the Department of Health and Human Services to protect public health. The organization ensures the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. It also supervises the nation's food supply, cosmetics, tobacco products, dietary supplements, and radiation-emitting products. The agency enforces the Federal Food, Drug, and Cosmetic Act along with Section 361 of the Public Health Service Act. Officials manage regulatory compliance across various industries, providing accurate health information to the public while mitigating diseases across multiple sectors.
Why it matters
The agency holds broad authority over consumer protection and medical oversight in the United States. Its responsibilities extend from pharmaceutical drugs and medical devices to consumer electronics and household products. Understanding the jurisdictional reach of the federal regulator helps clarify how medical tests and products undergo federal supervision.
What is confirmed
- The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services.
- The agency is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
- The primary focus of the Food and Drug Administration is enforcing the Federal Food, Drug, and Cosmetic Act.
What to watch next
- Official regulatory decisions regarding specific medical products under review by agency panels.
confidence 100%Sources used for this update (6)
- www.fda.gov — U.S. Food and Drug Administration
- www.fda.gov — Drugs | FDA
- en.wikipedia.org — Food and Drug Administration - Wikipedia
- www.usa.gov — Food and Drug Administration (FDA) | USAGov
- www.fda.gov — Food and Drug Administration | FDA
- www.fda.gov — What We Do | FDA
-
FDA Panel Recommends Approval of Grail Galleri Cancer Blood Test
An FDA advisory panel recommended approval of Grail Inc.'s Galleri multi-cancer early detection test on September 23. The committee voted 7-2, with one abstention, that the DNA-based test's benefits outweigh its risks and 10-0 that it is safe. While the test can screen for more than 50 types of cancer in healthy people using a single blood draw, the panel remained divided on effectiveness with a 6-4 vote. The test does not provide a diagnosis; positive results require additional medical care to confirm the presence of a tumor.
Why it matters
The Galleri test uses a single blood draw to look for signals of various tumors before symptoms appear. This regulatory step is significant for Bay Area biotech and investors like Samsung Electronics. The test is intended for adults aged 50 and older to be used alongside standard screening.
What is confirmed
- The FDA advisory panel voted 7-2, with one abstention, that the Galleri test offers more potential benefits than risks.
- The panel voted 10-0 that the test is safe for its proposed use.
- The Galleri test is designed to screen for more than 50 types of cancer in apparently healthy people.
- A narrow 6-4 vote was recorded regarding whether the test works.
- The test identifies signals of tumors but does not diagnose cancer.
- The panel's endorsement occurred on September 23.
Still unconfirmed
- The PATHFINDER 2 study showed that adding Galleri increased detected cancers more than six-fold with a very low false-positive rate.
- The panel's decision is expected to benefit Samsung Electronics and Samsung C&T.
What to watch next
- Final FDA approval decision for the Galleri test
- Publication of further research regarding the test's effectiveness in saving lives
confidence 95%Sources used for this update (15)
- www.wbaltv.com — FDA panel endorses first-of-a-kind cancer blood test - WBAL
- en.sedaily.com — FDA Panel Backs Grail Cancer Test, Lifting Samsung Bets
- www.newsbreak.com — CDC reports first measles death amid confusion over Pennsylvania cases - NewsBreak
- www.newsbreak.com — Israel’s Netanyahu takes the U.N. stage facing global isolation and a fight for his political future - ....
- www.klkntv.com — FDA panel endorses first-of-a-kind cancer blood test from Grail
- www.livingstonenterprise.net — FDA panel endorses first-of-a-kind cancer blood test from Grail - The Livingston Enterprise
- www.manilatimes.net — FDA panel endorses first-of-a-kind cancer blood test from Grail | The Manila Times
- www.ama-assn.org — Top news stories from AMA Morning Rounds®: Week of Sept. 21, 2026
- trailmix.cc — Only 35 More Days to Go – Trail Mix
- www.oncnursingnews.com — FDA Advisory Panel Votes to Approve GRAIL Galleri MCED ...
- www.ktvu.com — Bay Area biotech's groundbreaking blood test to detect 50+ cancers gets critical FDA panel approval | KTV....
- www.dlnnews.com — FDA panel endorses first-of-a-kind cancer blood test from Grail
-
FDA advisers endorse Grail's Galleri multi-cancer blood test
An FDA advisory panel voted to recommend the Galleri multi-cancer early detection test from Grail for approval. The committee voted 7-2 that the benefits of the test outweigh its risks and 10-0 that the test is safe for its proposed use. However, the panel was divided on effectiveness, with a narrow 6-4 vote regarding whether the test works. The test is designed to detect early signs of more than 50 types of cancer before symptoms appear.
Why it matters
Early detection of cancer typically requires specific screenings for individual organs. A single blood test capable of identifying dozens of cancer types would change how clinicians screen asymptomatic patients. Grail has previously conducted large prospective studies to test the detection of 17 cancer types.
What is confirmed
- The FDA advisory panel voted 10-0 that the Galleri test is safe for its proposed use.
- The committee voted 7-2 that the benefits of the Galleri test outweigh its risks.
- Panel members split 6-4 on the question of the test's effectiveness.
- The Galleri test aims to detect early signs of more than 50 types of cancer.
- Grail developed the multi-cancer early detection test.
What to watch next
- Final FDA decision on the commercial approval of the Galleri test
- Publication of further safety and performance data from the PATHFINDER 2 study
confidence 95%Sources used for this update (14)
- NPR — Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
- Nature — Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
- Mayo Clinic News Network — Multicancer blood test detects 17 cancer types in large prospective study
- AP News — FDA panel endorses first-of-a-kind cancer blood test from Grail
- Scientific American — Blood test for multiple cancers clears crucial hurdle on track to FDA approval
- ft.com — Cancer-screen blood test wins tepid support from US drug advisory panel
- The New York Times — F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
- seattletimes.com — FDA advisory panel endorses controversial cancer blood test
- PR Newswire — FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
- Reuters — US FDA advisers endorse Grail cancer test's benefits in key vote
- medicalxpress.com — FDA panel narrowly backs multi-cancer blood test despite doubts it works
- www.ntd.com — FDA Panel Backs Multi-Cancer Blood Test Despite Uncertainty Over Effectiveness
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community